Deblina Banerjee, Ph.D.

Deblina Banerjee, Ph.D.
Postdoctoral Fellow (Visiting)

Team Member of:

I am studying the epigenetic landscape of neuroblastoma (NB) and how it changes after treatment with agents such as retinoic acid.  My aim is to delineate the potential role of MYCN, a proto-oncogene that is amplified in NB, and EZH2, a component of PRC2, as critical epigenetic modifiers which, along with other transcription factors, might disrupt cell lineage commitment or cell fate determination.

 

Areas of Expertise
1) MYCN

Contact Info

Deblina Banerjee, Ph.D.
Center for Cancer Research
National Cancer Institute
Buildijng 10-CRC, Room 1-5816
Bethesda, MD 20892
Ph: 301-451-7049
deblina.banerjee@nih.gov

After graduating as a biotech engineer, my urge to better understand the complexity of genetic systems and work directly with patients, led me to pursue my Ph.D. on glaucoma, a complex ocular disorder. Keeping with the trend, I joined the CMBS family to study the complex pathophysiology of neuroblastoma (NB), a rare childhood cancer.

 

My research aims to elucidate the epigenetic landscape of NB and how it changes after treatment with agents (e.g.,. retionic acid) that cause growth arrest and differentiation, which might lead to the identification of new clinically relevant druggable targets. We aim to delineate the potential role, MYCN, proto – oncogene amplified in NB, and EZH2, a component of PRC2, as critical epigenetic modifiers which along with other transcription factors might disrupt cell lineage commitment or cell fate determination.